(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Manual for Tracking down Spending plan Agreeable Travel Objections - 2How to avoid or deal with an outrageous medical bill
- 3Paris Agreement target off the table, report says
- 4Russian billionaire says 12-hour days and 6-day workweeks could help save the economy
- 5Astronomers may have spotted the 1st known 'superkilonova' double star explosion
- $1,000 bribes, Mormon momfluencer mixers and making content to get plastic surgery: The wildest things I learned reporting my book
- Share your number one city visit transport that leaves a mark on the world wake up!
- What are the health benefits of whole milk for kids?
- Turning to turkey’s tryptophan to boost mood? Not so fast
- Careful Living: Embracing the Current Second
- The Force of Positive Reasoning: Day to day Attestations
- Watch This Glacier Race into the Sea
- Mexico says a third of 130,000 missing people might be alive, fueling criticisms by families
- Kansas school officials report high student illness, dismiss early
